Injectable Tissue Provides Significant, Long-Term Relief for Chronic Back Pain

FAIRFAX, Va., March 4, 2023 ~ A new study presented at the Society of Interventional Radiology Annual Scientific Meeting in Phoenix has found that a minimally invasive treatment, known as viable disc allograft supplementation, can provide significant improvement in pain and function for patients suffering from degenerative disc disease.

The treatment involves injecting specialized cells and fluid into a patient's damaged disc, encouraging the cells to regenerate with healthy tissue. Lead author Douglas Beall, M.D., FSIR, chief of radiology at Clinical Radiology of Oklahoma said: "The significant improvement in pain and function is promising for patients living with chronic low back pain – a condition that can greatly impact a person's quality of life. Back pain is the leading cause of limited activity and workplace absenteeism. This treatment may help patients return to a normal activity level for a longer period time."

The study involved fifty patients at nine sites, with 46 receiving allograft treatment and four receiving saline. The results showed that sixty percent of those who received allograft treatment reported a greater than 50% improvement in pain and 70% reported more than a 20-point improvement in their Oswestery Disability Index (ODI) scores. There were no persistent adverse events reported.

More on The Arizonar
Degenerative disc disease is the leading cause of chronic low back pain, which can lead to reduced functionality due to the discs cushioning the spine's vertebra wearing away. Beall said: "Existing treatment for chronic low back pain due to degenerative disc disease is often ineffective or the effects are short-lived. We need better treatments for this condition since conservative care is not providing the long-term outcomes that patients deserve. Injectable allograft treatment might be the answer for many people."

In addition to providing relief from chronic low back pain, use of allograft could even help decrease opioid use among patients with chronic low back pain, researchers said, which would be especially meaningful for younger patients who have years of function and quality of life to look forward to. The treatment requires no incisions and patients are able to go home on the same day. VIVIEX Biologics, Inc., who sponsored this study, also have Dr Beall as their medical consultant.

The results from this three-year voluntary extension trial suggest that viable disc allograft supplementation could be an effective way to provide relief from chronic low back pain associated with degenerative disc disease over a sustained period without any persistent adverse events being reported.
Filed Under: Business

Show All News | Report Violation


Latest on The Arizonar